Lysyl oxidases regulate fibrillar collagen remodelling in idiopathic pulmonary fibrosis
Autor: | Eric S. White, Janette K. Burgess, Delphine Sicard, Alen Faiz, Gavin Tjin, Daniel J. Tschumperlin, Eleanor P.W. Kable, Annabelle Mahar |
---|---|
Přispěvatelé: | Groningen Research Institute for Asthma and COPD (GRIAC), Restoring Organ Function by Means of Regenerative Medicine (REGENERATE) |
Jazyk: | angličtina |
Rok vydání: | 2017 |
Předmět: |
0301 basic medicine
MYOFIBROBLAST Fibrillar Collagens Medicine (miscellaneous) lcsh:Medicine FORCE MICROSCOPE NINTEDANIB Extracellular matrix Protein-Lysine 6-Oxidase Idiopathic pulmonary fibrosis Immunology and Microbiology (miscellaneous) Fibrosis Transforming Growth Factor beta Lung LOXL2 biology Chemistry Hydrogels Anatomy respiratory system Extracellular Matrix 3. Good health medicine.anatomical_structure 06 Biological Sciences 11 Medical and Health Sciences TRIAL Collagen Myofibroblast Research Article lcsh:RB1-214 EXPRESSION FIBROBLASTS MIGRATION Neuroscience (miscellaneous) Lysyl oxidase General Biochemistry Genetics and Molecular Biology Collagen Type I 03 medical and health sciences medicine lcsh:Pathology EXTRACELLULAR-MATRIX Humans 2ND-HARMONIC GENERATION lcsh:R Correction Transforming growth factor beta Second harmonic generation medicine.disease Idiopathic Pulmonary Fibrosis respiratory tract diseases 030104 developmental biology Case-Control Studies Cancer research biology.protein LUNG Developmental Biology |
Zdroj: | Disease models & mechanisms, 10(11), 1301-1312. COMPANY OF BIOLOGISTS LTD Disease Models & Mechanisms Disease Models & Mechanisms, Vol 10, Iss 11, Pp 1301-1312 (2017) |
ISSN: | 1754-8403 |
Popis: | Idiopathic pulmonary fibrosis (IPF) is a progressive scarring disease of the lung with few effective therapeutic options. Structural remodelling of the extracellular matrix [i.e. collagen cross-linking mediated by the lysyl oxidase (LO) family of enzymes (LOX, LOXL1-4)] might contribute to disease pathogenesis and represent a therapeutic target. This study aimed to further our understanding of the mechanisms by which LO inhibitors might improve lung fibrosis. Lung tissues from IPF and non-IPF subjects were examined for collagen structure (second harmonic generation imaging) and LO gene (microarray analysis) and protein (immunohistochemistry and western blotting) levels. Functional effects (collagen structure and tissue stiffness using atomic force microscopy) of LO inhibitors on collagen remodelling were examined in two models, collagen hydrogels and decellularized human lung matrices. LOXL1/LOXL2 gene expression and protein levels were increased in IPF versus non-IPF. Increased collagen fibril thickness in IPF versus non-IPF lung tissues correlated with increased LOXL1/LOXL2, and decreased LOX, protein expression. β-Aminoproprionitrile (β-APN; pan-LO inhibitor) but not Compound A (LOXL2-specific inhibitor) interfered with transforming growth factor-β-induced collagen remodelling in both models. The β-APN treatment group was tested further, and β-APN was found to interfere with stiffening in the decellularized matrix model. LOXL1 activity might drive collagen remodelling in IPF lungs. The interrelationship between collagen structural remodelling and LOs is disrupted in IPF lungs. Inhibition of LO activity alleviates fibrosis by limiting fibrillar collagen cross-linking, thereby potentially impeding the formation of a pathological microenvironment in IPF. Summary: Transforming growth factor-β-induced collagen remodelling is driven by enhanced lysyl oxidase expression in idiopathic pulmonary fibrosis. |
Databáze: | OpenAIRE |
Externí odkaz: |